Goal-directed De-escalation in ARDS
ARDS, Human, Sepsis, Severe
About this trial
This is an interventional treatment trial for ARDS, Human focused on measuring de-escalation therapy, acute respiratory distress syndrome, extravascular lung water, global end-diastolic volume, sepsis
Eligibility Criteria
Inclusion Criteria:
- The presence of sepsis ( the third international definition of sepsis and septic shock )
- The precence of ARDS (the Berlin definition of ARDS)
- mechanical ventilation before the study for at least 24 hrs
- the age of the patient > 18 years.
Exclusion Criteria:
- continuous infusion of norepinephrine in a dose exceeding 0.4 mcg/kg/min to maintain mean arterial pressure (MAP) within 65-75 mm Hg,
- morbid obesity with BMI > 40 kg/m2,
- severe brain injury,
- chronic kidney diseases,
- pregnancy,
- known irreversible underlying conditions such as end-stage neoplasms.
Sites / Locations
- City Hospital # 1 n.a. E.E. Volosevich
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
GEDVI-oriented de-escalation
EVLWI-oriented de-escalation
Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of GEDVI > 650 mL/m2 the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of GEDVI < 650 mL/m2 he target fluid balance is in the range of 0 to +3000 mL
Patients received de-escalation fluid management using either diuretics or ultrafiltration during continuous RRT. In the case of EVLWI > 10 mL/kg the primary goal of de-escalation is to obtain a cumulative fluid balance after 48 hrs from the study baseline of 0 to -3000 mL. In the case of EVLWI < 10 mL/kg, the target fluid balance is in the range of 0 to +3000 mL